Please provide your email address to receive an email when new articles are posted on . Lower Schirmer’s test score correlated with increased corneal staining and more severe disease burden among ...
Reproxalap Statistically Superior to Vehicle for Both Prespecified Primary Endpoints of Schirmer Test (p=0.0001) and ≥10 mm Schirmer Test Responder Proportions (p<0.0001) TRANQUILITY-2 Results May ...
LEXINGTON, Mass.--(BUSINESS WIRE)--Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra) today announced the designation of Schirmer test, a measure of tear production, as the sole primary endpoint in ...
Aldeyra Therapeutics, Inc. ALDX announced positive data from the vehicle-controlled crossover clinical study which evaluated its investigational product candidate, 0.25% reproxalap ophthalmic solution ...
Please provide your email address to receive an email when new articles are posted on . In this Healio Video Perspective from the virtual ARVO meeting, Jeffrey Gemi, MD, discusses the usability of ...
The primary endpoints of the TRANQUILITY-2 Trial are Schirmer test on the first day of dosing and ocular redness on the second day of dosing during the dry eye chamber. Top-line results from the trial ...
Reproxalap Statistically Superior to Vehicle for Both Primary Endpoints of Ocular Redness (P=0.0004) and Schirmer Test (P=0.0005) Schirmer Test ≥10mm Responder Analysis Multiplicity-Controlled ...
Please provide your email address to receive an email when new articles are posted on . WASHINGTON — In this Healio Video Perspective from the American Society of Cataract and Refractive Surgery ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results